NDC 0169-4501

WEGOVY

Semaglutide

WEGOVY is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Semaglutide.

Product ID0169-4501_424c481d-df27-4faa-ae93-ebe4460fd77d
NDC0169-4501
Product TypeHuman Prescription Drug
Proprietary NameWEGOVY
Generic NameSemaglutide
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2021-06-05
Marketing CategoryNDA /
Application NumberNDA215256
Labeler NameNovo Nordisk
Substance NameSEMAGLUTIDE
Active Ingredient Strength1 mg/.5mL
Pharm ClassesGLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0169-4501-14

4 SYRINGE, PLASTIC in 1 CARTON (0169-4501-14) > .5 mL in 1 SYRINGE, PLASTIC (0169-4501-01)
Marketing Start Date2021-06-05
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "WEGOVY" or generic name "Semaglutide"

NDCBrand NameGeneric Name
0169-4501WEGOVYsemaglutide
0169-4505WEGOVYsemaglutide
0169-4517WEGOVYsemaglutide
0169-4524WEGOVYsemaglutide
0169-4525WEGOVYsemaglutide
0169-4130Ozempicsemaglutide
0169-4132Ozempicsemaglutide
0169-4136Ozempicsemaglutide
0169-4181Ozempicsemaglutide
0169-4772Ozempicsemaglutide
50090-5138Ozempicsemaglutide
50090-5139Ozempicsemaglutide

Trademark Results [WEGOVY]

Mark Image

Registration | Serial
Company
Trademark
Application Date
WEGOVY
WEGOVY
79324913 not registered Live/Pending
Novo Nordisk A/S
2021-08-17
WEGOVY
WEGOVY
79303393 not registered Live/Pending
Novo Nordisk A/S
2020-10-29

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.